F
Fabrice Barlesi
Researcher at Aix-Marseille University
Publications - 666
Citations - 36214
Fabrice Barlesi is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 64, co-authored 582 publications receiving 25403 citations. Previous affiliations of Fabrice Barlesi include Institut Gustave Roussy & Nord University.
Papers
More filters
Journal ArticleDOI
IFCT-0504 trial: Mucinous (M) and nonmucinous (NM) cytologic subtypes interaction effect in first-line treatment of advanced bronchioloalveolar carcinoma (BAC) by erlotinib (E) or carboplatin/paclitaxel (C/P).
Jacques Cadranel,Radj Gervais,Marie Wislez,Patrick Merle,D. Moro-Sibilot,Virginie Westeel,Laurence Bigay-Game,E. Quoix,Sylvie Friard,Fabrice Barlesi,M. Zaegel,L. Moreau,Isabelle Monnet,J. Duhamel,G. Oliviero,Pierre-Jean Souquet,Luc Thiberville,Laurence Baudrin,Franck Morin,G. Zalcman +19 more
TL;DR: A multicentric randomized phase II trial to evaluate in first-line treatment E or C/P with a cross-over at progression and pemetrexed in third-line, the IFCT-0504 trial showed thatC/P is effective in both M- and NM-BAC; and E is as effective as C-P in NM- BAC, but less in M-Bac.
Journal ArticleDOI
1310PSurvival and safety of atezolizumab by best overall response (BOR) in the phase III NSCLC OAK study
F. De Marinis,Fabrice Barlesi,Achim Rittmeyer,J. von Pawel,J-Y. Han,Mark Kozloff,Alexander I. Spira,Louis Fehrenbacher,David R. Gandara,Wei Yu,Pei He,Cindy Yun,Marcus Ballinger,M. Gandhi,S. Gadgeel +14 more
Journal Article
Alveolar microlithiasis and immunological disorders.
Journal ArticleDOI
3MO Comprehensive biomarkers (BMS) analysis to predict efficacy of PD1/L1 immune checkpoint inhibitors (ICIs) in combination with chemotherapy: A subgroup analysis of the precision immuno-oncology for advanced non-small cell lung cancer (pioneer) trial
Fabrice Barlesi,Laurent Greillier,Florence Monville,C. Audigier Valette,Stéphanie Martinez,Nicolas Cloarec,S. Van Hulst,Luc Odier,Frédéric Vély,L. Juquel,Lombard Arnaud,Sivan M. Bokobza,Mourad Hamimed,M. Karlsen,P. Dufosse,Aurelie Pouchin,Lamia Ghezali,M. Le Ray,J. Fieschi-Meric,Sebastien Benzekry +19 more
TL;DR: The PIONeeR trial aims to predict response/resistance to PD1/L1 ICIs through a comprehensive multiparametric BMs analysis as mentioned in this paper , which is an unmet need in patients with advanced NSCLC.
Journal ArticleDOI
3128 EGFR, ALK, KRAS prognostic value in a large French prospective cohort of non-previously treated advanced NSCLC. Preliminary report of the IFCT-PREDICT.amm cohort
Jacques Cadranel,E. Quoix,Michael Duruisseaux,S. Friard,Elizabeth Fabre,Catherine Daniel,Virginie Westeel,Anne Madroszyk,Hervé Lena,Patrick Merle,Julien Mazieres,Eric Dansin,Arnaud Scherpereel,Sandrine Hiret,Bruno Coudert,P.J. Souquet,P. Missy,Franck Morin,G. Zalcman,Fabrice Barlesi +19 more